You are here: Home » International » News » Companies
Business Standard

Laobaixing, Yixintang in talks to create China's largest drugstore: Report

Shanghai-listed Laobaixing, formally known as LBX Pharmacy Chain Joint Stock Company and which boasts Tencent Holdings Ltd as a backer

Topics
pharmacy | China

Reuters  |  Hong Kong 

mergers
Photo: Shutterstock

China's Laobaixing and Yixintang Pharmaceutical Group Co Ltd are in advanced talks to create the country's biggest drugstore chain via a share swap, three people familiar with the matter said.

Laobaixing's founders, Xie Zilong and Chen Xiulan, are expected to have a bigger stake in the merged firm than Yixintang's founder Ruan Hongxian, said two of the people.

Shanghai-listed Laobaixing, formally known as LBX Chain Joint Stock Company and which boasts Tencent Holdings Ltd as a backer, has a market value of around $4.4 billion, while Shenzhen-listed Yixintang is valued at about $3.5 billion.

The talks have been ongoing for more than three months, the two people said. One person said the firms are aiming to finalise the deal in the coming days, adding that Laobaixing would remain the listed entity.

After the story was published, Yixintang said in a filing late on Monday that the report about the company being in talks with Laobaixing to create China's largest chain was untrue. Yixintang has nothing to disclose at this stage, it said in the filing.

Laobaixing did not respond to requests for comment.

The sources declined to be identified as the discussions were not public.

Shares in both firms initially climbed on the news of the merger talks but later gave up gains to be mostly flat in afternoon trade.

Tencent, which took a 1% stake in Laobaixing to become a strategic partner this year, has endorsed the merger and is planning to work with the combined firm to speed up implementation of a "smart retail" strategy, according to two people.

The tech giant is looking at helping with the integration of their online and physical store businesses and will help drive traffic through its messaging service WeChat as well as other platforms, said one person.

Tencent declined to comment.

Laobaixing, also backed by private equity firms FountainVest Partners and Primavera Capital, had 6.7 billion yuan ($1 billion) in revenue for the first half of the year, while Yixintang had 6 billion yuan, filings show.

Together they exceeded the 8.6 billion yuan in first-half sales for current industry leader, state-backed Sinopharm Holding Guoda Drugstores. Their combined number of stores at around 13,100 would also be more than double Guoda's.

China's drugstore market is, however, highly fragmented. According to market research firm Qianzhan, Guoda had a market share of 2.9% last year, ahead of Laobaixing with 2.6% and Yixintang with 2.4%.

Both Laobaixing and Yixintang sell pharmaceuticals, traditional Chinese medicine, nutritional supplements and medical equipment. They also complement each other geographically with Laobaixing strong in central and eastern while Yixintang has focused on the southwest of China, particularly its home province of Yunnan.

Laobaixing, established in 2001, is 33% held by its founders. For years it counted EQT as a key backer but the Swedish private equity firm sold its 25% stake to FountainVest and Primavera for $557 million a year ago.

Yixintang, founded in 1981, is 31% owned by founder Ruan.

 

(Reporting by Julie Zhu; Editing by Edwina Gibbs and Susan Fenton)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, November 02 2020. 20:05 IST
RECOMMENDED FOR YOU